Evoke Pharma Inc (NASDAQ:EVOK) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.93 and traded as low as $0.97. Evoke Pharma shares last traded at $1.00, with a volume of 817,116 shares changing hands.

Several research firms have weighed in on EVOK. ValuEngine raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th.

The firm’s 50-day moving average price is $0.93 and its 200 day moving average price is $0.91. The company has a market capitalization of $22.56 million, a P/E ratio of -2.10 and a beta of 1.64.

Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. As a group, analysts anticipate that Evoke Pharma Inc will post -0.35 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Evoke Pharma stock. Marshall Wace LLP bought a new position in shares of Evoke Pharma Inc (NASDAQ:EVOK) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 92,406 shares of the specialty pharmaceutical company’s stock, valued at approximately $139,000. Marshall Wace LLP owned approximately 0.40% of Evoke Pharma at the end of the most recent reporting period. Institutional investors own 5.50% of the company’s stock.

Evoke Pharma Company Profile (NASDAQ:EVOK)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Article: Derivative

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.